ArticleJACC. Case reports2025
Early TAVR Explantation Due to a Large Mobile Leaflet Mass and Severe Prosthetic Valve Stenosis.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter aortic valve replacement (TAVR) is a common treatment for aortic stenosis (AS). Although it is generally safe, its rising use has led to increased device failures and complications requiring surgery. Data on surgical explantation after TAVR remain limited. CASE PRESENTATION: An 85-year-old woman, 1-year post-TAVR, developed recurrent AS. Imaging revealed a mobile transvalvular mass and subvalvular pannus. Medical therapy failed, and because of stroke risk, she underwent TAVR explantation, subannular pannus resection, left ventricular outflow tract repair, and surgical aortic valve replacement. Histology confirmed leaflet thrombosis and valve deterioration. DISCUSSION: Surgical explantation after TAVR occurs in about 1% of cases. Among these, 47% require surgical aortic valve replacement, and 53% need additional procedures, often involving the aorta. Recognizing structural valve deterioration and its cause is critical. TAKE-HOME MESSAGE: As TAVR use rises, so will complications. Further research is needed to enhance management and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.